GlassScriptPhysician profile
Joyce L Roberts
NPI 1962400481
$1,612.75
in general payments reported to CMS, 2019-2025
20 companies · $628 in 2025
The $628 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $350 · 2023: $36.12 · 2024: $599 · 2025: $628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,262.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $350.00 | 2019 | |
| Novo Nordisk INC | $286.60 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.64 | 2024-2025 | Jardiance |
| Abbvie INC. | $117.53 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $109.64 | 2024-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $103.49 | 2024-2025 | Zepbound, Mounjaro |
| Amgen INC. | $99.59 | 2024-2025 | Repatha, Otezla, Otezla |
| Exact Sciences Corporation | $89.76 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $65.74 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.18 | 2024 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $35.83 | 2024 | Rexulti |
| Astellas Pharma US INC | $28.42 | 2024 | Veozah |
| Medtronic, INC. | $26.01 | 2024 | Intellis Adaptivestim |
| Merck Sharp & Dohme LLC | $24.66 | 2025 | Capvaxive, Gardasil 9 |
| Lucid Diagnostics INC. | $22.14 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $20.59 | 2025 | Odactra, Ragwitek, Grastek |
| Shield Therapeutics INC | $18.40 | 2024 | |
| Glaxosmithkline, LLC. | $17.22 | 2025 | Shingrix |
| Azurity Pharmaceuticals, INC. | $17.11 | 2025 | |
| Corcept Therapeutics | $14.20 | 2025 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joyce Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.